VIATRIS INC. Revenue from Contract with Customer, Excluding Assessed Tax
VIATRIS INC. (VTRS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $3.75 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $3.75B, a 4.96% increase year-over-year.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.51B, a 8.22% increase year-over-year.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.69B, a 4.99% increase year-over-year.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.75B, a 0.25% increase year-over-year.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $14.25B, a 3.01% decline from fiscal 2024.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $14.69B, a 4.52% decline from fiscal 2023.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $15.39B, a 5.12% decline from fiscal 2022.
- VIATRIS INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $16.22B, a 8.96% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 4 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 7 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 11 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.75B 10-Q · filed 2026-08-06 | $7.26B 10-Q · filed 2026-08-06 | $10.95B derived: sum of 3 quarters · filed 2026-08-06 | $14.69B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $3.51B 10-Q · filed 2026-05-07 | $7.20B derived: sum of 2 quarters · filed 2026-05-07 | $10.95B derived: sum of 3 quarters · filed 2026-05-07 | $14.52B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $3.69B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.44B derived: sum of 2 quarters · filed 2026-02-26 | $11.01B derived: sum of 3 quarters · filed 2026-08-06 | $14.25B 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $3.75B 10-Q · filed 2025-11-06 | $7.32B derived: sum of 2 quarters · filed 2026-08-06 | $10.56B 10-Q · filed 2025-11-06 | $14.08B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $3.57B 10-Q · filed 2026-08-06 | $6.81B 10-Q · filed 2026-08-06 | $10.33B derived: sum of 3 quarters · filed 2026-08-06 | $14.07B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $3.24B 10-Q · filed 2026-05-07 | $6.76B derived: sum of 2 quarters · filed 2026-05-07 | $10.50B derived: sum of 3 quarters · filed 2026-05-07 | $14.28B derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $3.52B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.25B derived: sum of 2 quarters · filed 2026-02-26 | $11.04B derived: sum of 3 quarters · filed 2026-02-26 | $14.69B 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $3.74B 10-Q · filed 2025-11-06 | $7.52B derived: sum of 2 quarters · filed 2025-11-06 | $11.18B 10-Q · filed 2025-11-06 | $15.00B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $3.79B 10-Q · filed 2025-08-07 | $7.44B 10-Q · filed 2025-08-07 | $11.27B derived: sum of 3 quarters · filed 2026-02-26 | $15.20B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $3.65B 10-Q · filed 2025-05-08 | $7.48B derived: sum of 2 quarters · filed 2026-02-26 | $11.41B derived: sum of 3 quarters · filed 2026-02-26 | $15.32B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $3.83B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.76B derived: sum of 2 quarters · filed 2026-02-26 | $11.67B derived: sum of 3 quarters · filed 2026-02-26 | $15.39B 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $3.93B 10-Q · filed 2024-11-07 | $7.84B derived: sum of 2 quarters · filed 2024-11-07 | $11.56B 10-Q · filed 2024-11-07 | $15.43B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $3.91B 10-Q · filed 2024-08-08 | $7.63B 10-Q · filed 2024-08-08 | $11.50B derived: sum of 3 quarters · filed 2025-02-27 | $15.56B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $3.72B 10-Q · filed 2024-05-09 | $7.59B derived: sum of 2 quarters · filed 2025-02-27 | $11.65B derived: sum of 3 quarters · filed 2025-02-27 | $15.76B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $3.87B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.93B derived: sum of 2 quarters · filed 2025-02-27 | $12.04B derived: sum of 3 quarters · filed 2025-02-27 | $16.22B 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $4.07B 10-Q · filed 2023-11-08 | $8.17B derived: sum of 2 quarters · filed 2023-11-08 | $12.35B 10-Q · filed 2023-11-08 | $16.68B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $4.11B 10-Q · filed 2023-08-07 | $8.28B 10-Q · filed 2023-08-07 | $12.61B derived: sum of 3 quarters · filed 2024-02-28 | $17.14B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $4.18B 10-Q · filed 2023-05-08 | $8.51B derived: sum of 2 quarters · filed 2024-02-28 | $13.03B derived: sum of 3 quarters · filed 2024-02-28 | $17.59B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $4.33B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.85B derived: sum of 2 quarters · filed 2024-02-28 | $13.41B derived: sum of 3 quarters · filed 2024-02-28 | $17.81B 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $4.52B 10-Q · filed 2022-11-07 | $9.08B derived: sum of 2 quarters · filed 2022-11-07 | $13.48B 10-Q · filed 2022-11-07 | $17.07B derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $4.56B 10-Q · filed 2022-08-08 | $8.96B 10-Q · filed 2022-08-08 | $12.55B derived: sum of 3 quarters · filed 2023-02-27 | $15.50B derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $4.40B 10-Q · filed 2022-05-09 | $7.99B derived: sum of 2 quarters · filed 2023-02-27 | $10.94B derived: sum of 3 quarters · filed 2023-02-27 | |||||
| 2020-12-31 | $3.59B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $6.54B derived: sum of 2 quarters · filed 2023-02-27 | $11.82B 10-K · filed 2023-02-27 | |||||
| 2020-09-30 | $2.95B 10-Q · filed 2021-11-08 | $8.23B 10-Q · filed 2021-11-08 | ||||||
| 2020-09-27 | $0.00 10-Q · filed 2020-11-10 | $2.70B derived: sum of 2 quarters · filed 2021-08-09 | $0.00 10-Q · filed 2020-11-10 | |||||
| 2020-06-30 | $2.70B 10-Q · filed 2021-08-09 | $5.28B 10-Q · filed 2021-08-09 | ||||||
| 2020-06-28 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||||||
| 2020-03-31 | $2.59B 10-Q · filed 2021-05-10 | |||||||
| 2020-03-29 | $0.00 10-Q · filed 2020-05-12 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2020-05-07 | $11.37B 10-K · filed 2022-02-28 | ||||||
| 2019-09-29 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 | |||||||
| 2018-12-31 | $11.27B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |